Lytix Biopharma's Ruxotemitide-Pembrolizumab Combination Meets Primary Endpoint in Phase II Melanoma Trial

• Lytix Biopharma’s Phase II NeoLIPA trial met its primary goal testing ruxotemitide with pembrolizumab before surgery in resectable melanoma.
• The combination met the study’s success criterion for eliminating viable cancer cells from surgically removed tumors, with no new safety signals identified.
• Full results will be presented at an upcoming international oncology conference.
• A planned randomized Phase III trial will compare the combination with pembrolizumab alone, measuring event-free survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via NewsWeb, the disclosure sustem operated by Euronext Oslo (Ref. ID: 202611030100OSLOBORSNEWS__EN_D256775D9794F005E81272E024D60D3), on November 03, 2026, and is solely responsible for the information contained therein.